Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 
Bristol-Myers Squibb Co at Sanford C Bernstein Strategic Decisions Conference Transcript
Jun 02, 2022 / 12:00PM GMT
Wimal Kapadia
Sanford C. Bernstein & Co., LLC., Research Division - Research Analyst
Good morning, everybody, and thank you for joining today. I'm Wimal Kapadia, the EU biopharma analyst here at Bernstein. It's my great pleasure to introduce Giovanni Caforio, CEO of Bristol-Myers Squibb; and Samit Hirawat, Chief Medical Officer at BMS. Thank you for your time. We really appreciate it.
Giovanni Caforio
Bristol-Myers Squibb Company - Chairman of the Board & CEO
Thanks, Wimal.
Wimal Kapadia
Sanford C. Bernstein & Co., LLC., Research Division - Research Analyst
(Operator Instructions) And it's nice to see we've already got a few questions submitted, so thank you very much. I think with that, we can kick off. And I think, Giovanni, we'll sort of jump straight into Q&A if that works.
Giovanni Caforio
Bristol-Myers Squibb Company - Chairman of the Board & CEO
That's perfect, thank you.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers